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ABSTRACT
Ruta angustifolia (L.) Pers. is a Rutaceous species which contains various anthranilic acid derived alkaloids including 
the bioactive quinolones. This study is aimed at identifying the antimicrobial active alkaloids of R. angustifolia and 
evaluating their potential as synergistic enhancers in alkaloid-antibiotic combinations. Antimicrobial bioautography-
guided isolation of alkaloidal fractions of R. angustifolia leaves has led to the identification of 2,3-dimethoxy-1-hydroxy-
10-methylacridone [arborinine]; and 4,7,8-trimethoxyfuro[2,3-b]quinoline [skimmianine]; together with the major 
active alkaloid, 1-methyl-2-[3’,4’-methylenedioxyphenyl]-4-quinolone [graveoline]. Graveoline showed Minimum 
Inhibitory Concentration (MIC) values ranging from 500 to 1000 µg/mL against Staphylococcus aureus ATCC 25923, 
Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922. Checkerboard assay for antimicrobial combination 
effects between graveoline with either erythromycin or vancomycin showed enhancement of the antimicrobial activity 
of both antibiotics with Fractional Inhibitory Concentration Indices (FICI) ranged from 0.37 to 1.50. Synergistic effect 
with FICI of 0.37 was observed for graveoline-erythromycin combination against S. aureus compared to FICI of 1.00 for 
ciprofloxacin-erythromycin additive effect. Graveoline was a potential candidate for antimicrobial combination agent 
especially against S. aureus. The result supports the idea of using plant metabolites as antimicrobial synergistic agents.
Keywords: Antimicrobial; graveoline; Ruta angustifolia; synergistic enhancer
ABSTRAK
Ruta angustifolia (L.) Pers. adalah spesies Rutaceae yang mengandungi pelbagai alkaloid yang hasilkan daripada asid 
anthranilik seperti alkaloid quinolon. Kajian ini bertujuan untuk mengenal pasti alkaloid aktif daripada R. angustifolia 
dan potensinya sebagai penggalak kesan sinergi bersama antibiotik terpilih. Pemencilan alkaloid aktif berpandukan 
bioautografi antimikrob daripada pecahan ekstrak daun R. angustifolia berjaya mengenal pasti 2,3-dimetoksi-1-
hidroksi-10-metilakridon [arborinin]; dan 4,7,8-trimetoksifuro[2,3-b]quinolin [skimmianin]; dan akaloid aktif utama 
1-metil-2-[3’,4’-metilenedioksifenil]-4-quinolon [graveolin]. Graveolin menunjukkan Kepekatan Perencatan Minima 
(MIC) pada julat antara 500 dan 1000 µg/mL terhadap Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 
29212 dan Escherichia coli ATCC 25922. Gabungan antara graveolin dan erithromicin atau vankomicin yang dinilai 
melalui Assay Checkerboard menunjukkan bahawa graveolin meningkatkan aktiviti kedua-dua antibiotik dengan Indeks 
Pecahan Kepekatan Perencatan (FICI) antara 0.37 dan 1.50. Kesan sinergi dengan nilai FICI 0.37 ditunjukkan oleh 
gabungan graveolin-erithromicin terhadap S. aureus berbanding kesan tambahan dengan nilai FICI 1.00 oleh gabungan 
ciprofloxacin-erithromicin. Graveolin mempunyai potensi sebagai agen gabungan antimikrob terutama terhadap S. 
aureus. Keputusan kajian ini menyokong penggunaan metabolit daripada tumbuhan sebagai agen sinergi antimikrob.
Kata kunci: Antimikrob; graveolin; penggalak sinergistik; Ruta angustifolia
INTRODUCTION
The resistance in current antibiotics which restricts their 
effectiveness in the standard treatment of infections 
has dramatically increasing due to global emergence 
of multi-drug resistant bacterial strains. The global 
concern on the present updates on widespread antibiotic 
resistance include treatment failure of Escherichia 
coli, Klebsiella pneumoniae, Staphylococcus aureus 
and Enterobacteriaceae infections to fluroquinolones, 
carbapenem, the first line drugs treatment and colistin, 
respectively. Erythromycin, vancomycin and ciprofloxacin 
are among the antibiotics which are prone to be degraded 
by the bacterial enzymatic resistance mechanism (WHO 
2017). One of the strategies employed in overcoming 
limited number of antimicrobial agents that are currently 
available in fighting the highly resistant strains is antibiotic 
combination therapy (Tamma et al. 2012).
 Plant-based natural product is one of the ideal 
candidates in discovering new class of antimicrobial agent 
and has contributed in surviving the increasing number of 
bacterial resistance towards currently existing antibiotics 
(Abreu et al. 2012). These phytochemicals are potential 
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antimicrobial combination agents since several compounds 
have also been found to be synergistic enhancers (Kyaw et 
al. 2012; Linda et al. 2011). Although they may possessed 
weak inhibitory activity alone but when combined 
with certain antibiotics they enhanced the activity of 
the later (Kyaw et al. 2012). The combination also has 
been recognised as important approach for delaying the 
emergence of bacterial resistance and may also eventually 
reduced the undesirable side effects of the antibiotics 
(Hemaiswarya & Doble 2010). 
 Rutaceae has been a source of interest for its novel 
anthranillic acid derived alkaloids with biologically 
active antibacterial and antifungal properties (da Silva et 
al. 2013). Ruta angustifolia (Garuda or Aruda in Malay) 
of the Rutaceae is one of the rich sources of anthranilic 
acid derived alkaloids including acridone, quinoline, 
quinolone and furoquinoline alkaloids (El Sayed et al. 
2003). It is a small shrub with strong and unpleasant smell 
and used traditionally for treating ear infection, boils and 
bruised (Shamsul et al. 2003). Alkaloids are among the 
bioactive phytochemicals which are responsible for the 
antimicrobial activity possessed by Ruta species (Raj et 
al. 2013). The reported alkaloids of R. angustifolia include 
rutaverine, arborinine, fagarine, graveolinine, graveoline 
and skimmianine (Koh et al. 2009). The present study 
was undertaken to isolate and identify the antimicrobial 
active alkaloids of R. angustifolia, and evaluating their 
potential as synergistic enhancers in alkaloid-antibiotic 
combinations with either erythromycin or vancomycin.
MATERIALS AND METHODS
INSTRUMENTATIONS
Spots on TLC chromatograms were visualized under UV 
lights at 254 and 365 nm by using Fluorescent Analysis 
Cabinet (SPECTROLINE, CM-10). Alkaloid purification was 
performed using chromatotron (Model 7924T, Harrison 
Research U.S.A) with silica gel containing gypsum Kieselgel 
60 PF254 (Merck, 7749) as the stationary phase. Melting 
point was determined using digital melting point apparatus 
(Stuart’s SMP20) equipped with microscope. Ultraviolet 
spectra were recorded in methanol using HITACHI, U-2900 
Spectrophotometer. The infrared spectra were recorded 
on Perkin Elmer FTIR Spectrum 2000 Spectrometer with 
chloroform as solvent. 1H NMR and 13C NMR spectra were 
recorded on a Bruker, 500 MHz (Avance III, Ultrashield 
Plus) Spectrometer. MS were recorded by direct probe 
method using Thermofinnigan Trace GC-Polaris-Q GCMS. 
PLANT MATERIALS
Ruta angustifolia (L.) Pers. was purchased at Muar, Johor, 
Malaysia. The plant species was verified by Dr. Shamsul 
Khamis, the botanist of Herbarium, Universiti Kebangsaan 
Malaysia (UKMB). A voucher specimen (PIIUM 0002-1) 
was deposited at the Herbarium, Kulliyyah of Pharmacy, 
International Islamic University Malaysia.
EXTRACTION
The dried leaves (400 g) were defatted with hexane and 
then extracted with acetone (4 L) using soxhlet apparatus. 
The extract was concentrated to 1/8 of its original volume 
and extracted exhaustively with 2% hydrochloric acid until 
Mayer’s test became  negative. The acidic aqueous solution 
was basified with 0.5 M sodium hydroxide to pH8-9 and 
extracted with CHCl3 until extinction. The crude alkaloidal 
extract was then dried using sodium sulphate anhydrous, 
filtered and evaporated to dryness (7.1 g). 
FRACTIONATION AND ISOLATION
The extract (2.6 g) was fractionated by column 
chromatography on silica gel (100 g, 70-230 mesh) 
(column 3 × 100 cm) eluting successively with hexane/
CH2Cl2 (4:6 - 0:1, 5% increment of CH2Cl2), then CH2Cl2/
EtOAc (9:1 - 1:1, 10% increment of EtOAc) and a gradient 
of CH2Cl2/EtOAc/Me2CO (10:9:1-2:7:1, 10% and 1% 
increment of EtOAc and Me2CO, respectively, to furnished 
10 fractions (F1 - F10). Fractions F3, F4 and F10 were 
subjected to bioautography agar overlay assay which 
showed RA2, RA3 and RA9 as the antimicrobial active 
alkaloids. Fraction F3 (50 mg) was rechromatographed by 
column chromatography (40 g) (column 2 × 40 cm) with 
hexane/CH2Cl2 (4:6-2:8, 1% increment of CH2Cl2 then 
1-2% of EtOAc) to give 3 fractions (F3-1 - F3-3). Fraction 
F3-3 (150 mg) was further purified by chromatotron (1 
mm thickness) with 100% pet-ether then a gradient of 
pet-ether/CH2Cl2 (99:1-8:2, 1% increment of CH2Cl2 then 
1% increment of EtOAc with subsequent 1% decrement of 
CH2Cl2. RA2 or arborinine (1) was eluted with pet-ether/
CH2Cl2/EtOAc (80:6:14) (30 mg, 1.2%). A total of 20 
mg Fraction F4 was separated by chromatotron (1 mm 
thickness) with mixture of RA3 or skimmianine (2) (0.8 
mg, 0.03%) was purified from fraction F4 (20 mg) by 
using chromatotron (1 mm thickness) eluted with pet-ether/
CH2Cl2/EtOAc (80:11:9) at the flow rate of 2 to 3 mL/min. 
Fraction F10 (120 mg) was rechromatographed on silica 
gel (15 g) (column 2 × 20 cm) eluting consecutively with 
pet-ether/CH2Cl2 (1:1 - 0:1, 10% increment of CH2Cl2) and 
CH2Cl2/MeOH (99:1 and 98:2). RA9 or graveoline (3) was 
eluted with CH2Cl2/MeOH (98:2) (80 mg, 3.1%).
ANTIMICROBIAL ACTIVITY
TEST MICROORGANISMS
Three bacterial strains of American Type Culture 
Collection (ATCC), namely Staphylococcus aureus ATCC 
25923, Escherichia coli ATCC 25922 and Enterococcus 
faecalis ATCC 29212 were used in this study.
INOCULA FOR ANTIMICROBIAL TESTS
The inocula for antimicrobial testing were prepared 
according to Rahalison et al. (1991). The inoculum size 
of 18 h culture incubated at 37°C was adjusted by using 
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UV spectrophotometer to an absorbance of 0.11 to 0.12 
at 600 nm.
BIOAUTOGRAPHY AGAR OVERLAY ASSAY
This assay was performed according to the bioautographic 
procedures (Rahalison et al. 1991) with a few modifications. 
All fractions were chromatographed on 4 cm × 10 cm 
TLC commercial aluminium sheets Silica gel 60F254 of 
layer thickness 0.2 mm. The chromatogram was rapidly 
distributed with 5 mL of inoculated molten agar at 35°C. 
After solidification of the agar, the TLC plates were kept 
in sterile petri dishes lined with moist filter papers and 
incubated at 37°C for 24 h. The plates were sprayed 
with an aqueous solution of 0.5% 2-[4-iodo-phenyl]-3-
[4-nitrophenyl]-5-phenyl-tetrazolium chloride (INT) and 
reincubated for 4 h. The active alkaloids were detected 
as the clear zones against a pink background of viable 
microbes. The reference chromatograms were visualized 
under UV lights and sprayed with Dragendorff’s reagent.
BROTH MICRODILUTION ASSAY
The minimum inhibitory concentrations (MICs) of 
graveoline and selected antibiotics were determined 
in triplicate against the test microorganisms by broth 
microdilution assay following the Clinical and Laboratory 
Standards Institute (CLSI) 2006 method with some 
modifications. Stock solution of gaveoline was two-
fold serially diluted in 96 well microtiter plate to obtain 
concentrations ranging from 1.56 to 1000 µg/mL. Standard 
antibiotics were prepared at a few ranges of concentrations 
from 0.48 to 500 µg/mL by two-fold serial dilution of two, 
five or ten times diluted stock solution of 1000 µg/mL. 
The microbial inocula were diluted hundred times to an 
approximate concentration of 1 × 105 colony forming unit 
(CFU)/mL with sterile broth. Each well contained a final 
volume of 200 µL of 180 µL of inoculated broth and 20 
µL of tested solution. The assay was repeated with diluents 
to check their effects on bacterial growth. Wells with 
bacterial suspension and uninoculated broth are included 
as normal growth and sterility control, respectively. The 
plates were incubated for 18 h at 37°C. 10 µL of 0.25% 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT) was added to each well subsequent to 
incubation for another 30 min. A colour change from 
yellow to blue indicated the presence of viable bacteria. 
MIC was recorded as the lowest concentration with no 
colour changes. The minimum bactericidal concentration 
(MBC) was determined by streaking a loopful of mixture 
from each well with no colour changes onto agar and 
incubated at 37°C for 24 h. MBC was recorded as the lowest 
concentration with no bacterial growth.
CHECKERBOARD ASSAY
The antimicrobial combination effects between 
graveoline and either erythromycin or vancomycin were 
studied following the CLSI 2006 guideline with some 
modifications. Two-fold serial dilutions of graveoline and 
antibiotic alone were performed in a volume of 20 μL per 
well in the first column and row of a 96-well microtiter 
plate, respectively. For graveoline-antibiotic combination, 
10 uL of each concentration of a serially diluted antibiotic 
solution was put in each well of the same remaining row of 
the plate. Then, each well was added with 180 μL of 100 
fold diluted inoculum. After 60 min incubation at room 
temperature, 10 μL of each concentration of a serially 
diluted graveoline solution was added in each well of the 
same column, so that each row contained a fixed amount 
of antibiotic while decreasing amounts of graveoline. 
All plates were incubated at 37°C for 18 h and the MIC 
values were confirmed by 0.25% MTT. The fractional 
inhibitory concentration (FIC) and the FIC indices (FICI) 
were calculated and interpreted following Orhan et al. 
(2005). The results were determined from the majority of 
three independent tests. The procedure was repeated for 
ciprofloxacin-antibiotic combination where ciprofloxacin 
FIGURE 1. Antimicrobial bioautographic profile of fraction R10 of R. angustifolia leaves alkaloidal extract showing RA9 or 
graveoline as the active alkaloid of the fraction, (a) and (b) reference chromatograms viewed under UV254 and UV365 light, 
respectively, (c) reference chromatogram sprayed with Dragendorff’s reagent (d), (e) & (f) bioautograms against S. aureus 
ATCC 25923, E. faecalis ATCC 29212 and E. coli ATCC 25922, respectively. Chromatographic conditions: pre-coated 
aluminium silica gel 60 F254 of 0.2 mm thickness, solvent system, CH2Cl2:MeOH (9:1)
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TABLE 1. Quantitative antimicrobial activity of graveoline from R. angustifolia and  
selected antibiotic standards
Test compound
Antimicrobial Activity (μg/mL)
S. aureus E. faecalis E. coli
MIC MBC MIC MBC MIC MBC
Graveoline
Ciprofloxacin
Erythromycin
Vancomycin
1000
0.195
1.098
2.50
>1000
0.195
1.098
2.50
500
1.562
0.78
3.13
1000
1.562
0.78
3.13
1000
0.039
50
250
>1000
0.039
50
500
was used as the reference for quinolone antimicrobial 
agent.
RESULTS AND DISCUSSION
Antimicrobial bioautography-guided isolation of alkaloidal 
fractions of R. angustifolia leaves has led to the 
identification of a major active alkaloid identified as 
graveoline (3) together with arborinine (1) and the minor 
alkaloid, skimmianine (2) (Figures 1 & 2). Graveoline 
possessed MIC values of 500 µg/mL against E. faecalis 
and 1000 µg/mL for S. aureus and E. coli (Table 1). The 
susceptibility values are within the range regarded for 
antimicrobial active phytochemicals (Monte et al. 2014). 
Antimicrobial active alkaloids may possess different 
mechanism of action than those of antibiotics which 
might potentiate the activity of the later when used in 
combination (Cushnie et al. 2014). Therefore, combination 
of graveoline, a natural 4-quinolone alkaloid with either 
erythromycin, a macrolide or vancomycin, a glycopeptide 
was performed with the objective of achieving higher 
efficacy in their activity with desirable synergistic effect 
possible for preventing drug resistance in the future. The 
combination effects were compared to that of ciprofloxacin 
which is a synthetic quinolone antimicrobial agent. 
 Graveoline possesses a structural characteristic of 
quinolone antimicrobial agent by bearing completely 
aromatic 4-quinolone ring with specific substituents at 
C-1, C-5 and C-8 but lacking in a 4-pyridone ring with 
3-carboxyl group which is the essential pharmacophore for 
exerting significant antibacterial activity (Chung et al. 2015; 
Emami et al. 2005). Nevertheless, it could be presumed 
that graveoline might possesses a few characteristics 
mechanism of action of the quinolones although at weaker 
activity. The graveoline-antibiotic interactions against S. 
aureus, E. faecalis and E. coli were recorded as synergy, 
partial synergy, additive and indifference, respectively, 
based on their FICI values (Orhan et al. 2005) (Table 2). The 
MICs of both graveoline and antibiotics were substantially 
reduced although to a variable extent as compared to the 
values when tested alone against S. aureus and E. coli. 
S. aureus was the most susceptible microbe towards 
graveoline-antibiotic interactions.  
 Graveoline-erythromycin combination resulted in 
synergy effect with the FICI of 0.37 and reduced MIC by 
FIGURE 2. Antimicrobial active alkaloids of Ruta angustifolia
6-folds and 4-folds for graveoline and erythromycin, 
respectively. Graveoline-vancomycin interaction produced 
partial synergy effect with FICI value of 0.5. Erythromycin 
and vancomycin are clinically used antibiotics particularly 
against Gram-positive bacterial infections. Erythromycin 
disrupts protein synthesis by inhibiting peptide elongation 
on the ribosome (Gaynor & Mankin 2003) whereas 
vancomycin is an inhibitor to cell wall peptidoglycan 
synthesis (Kang & Park 2015). The combination effects 
could be attributed to the dual actions of both agents at 
different target sites of the bacterial cells. Indifference 
effect with 2-folds reduction to the MIC of erythromycin 
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was produced in graveoline-antibiotic combinations 
against E. faecalis. The results showed that graveoline-
antibiotic actions occurred at a different susceptibility 
degree against different bacteria. 
 Both graveoline-antibiotic combinations against E. 
coli indicated a partial synergy with 4-folds reduction 
in the MIC of graveoline and 2-folds reduction of both 
erythromycin and vancomycin. Although vancomycin is 
considered inactive against Gram-negative bacteria due 
to variety of mechanisms involve in its cell wall synthesis 
and factors that affect membrane permeability (Kang 
& Park 2015), the resulted partial synergy effect for its 
combinations with graveoline suggested for effective 
combination for glycopeptide against Gram-negative E. 
coli. The partial synergy could be attributed to the actions 
of both agents at different targets consisting of disruption 
of cell wall synthesis by vancomycin which increase 
membrane permeability of graveoline to its target sites 
while inhibition of protein synthesis by erythromycin 
enhanced graveoline activity. 
 Combinations involving ciprofloxacin have resulted 
in additive interaction by which in every combination, 
both combined antibiotics exhibited 2-folds of MIC 
reduction and thus gave the FIC index of 1.00 against both 
Gram-positive S. aureus and E. faecalis. The result is 
in agreement to the previous finding on the influence of 
non-quinolone antimicrobial agents such as macrolides 
(Gradelski et al. 2001) and glycopeptides (Noviello et 
al. 2001) which demonstrated additive interactions with 
ciprofloxacin by all dual drug combinations. In E. coli, 
ciprofloxacin-erythromycin combination achieved partial 
synergy by 32-folds reduction in the MIC of erythromycin. 
A synergistic interaction was achieved for ciprofloxacin 
and vancomycin combination with 16-folds reduction of 
the MIC of the former and enhancement of the antimicrobial 
activity of the later by 32-folds. Ciprofloxacin is a broad 
spectrum antibiotic which is more susceptible to Gram-
negative bacteria than Gram-positive bacteria. It rapidly 
inhibits bacterial growth by primarily interfering with the 
DNA synthesis in combination with its efficient membrane 
permeability (Cramariuc et al. 2012) which resulted to a 
noticeable reduction of erythromycin and vancomycin. 
The findings showed that graveoline was a synergistic 
enhancer to erythromycin which is superior combination 
TABLE 2. Antimicrobial combination effects between graveoline and either erythromycin or vancomycin against S. aureus ATCC 
25923, E. faecalis ATCC 29212 and E. coli ATCC 25922 with comparison to that of ciprofloxacin
Bacteria Combination MIC alone(μg/mL)
MIC in combination 
(μg/mL) FIC FICI Combination effect
S. aureus
ATCC 25923
Graveoline
Erythromycin
1000
1.098
125
0.274
0.12
0.25 0.37 Synergy
Graveoline
Vancomycin
1000
2.50
250
0.625
0.25
0.25 0.50 Partial synergy
Ciprofloxacin
Erythromycin
0.195
1.098
0.098
0.547
0.50
0.50 1.00 Additive
Ciprofloxacin
Vancomycin
0.195
2.50
0.098
1.25
0.50
0.50 1.00 Additive
E. faecalis 
ATCC 29212
Graveoline
Erythromycin
500
0.781
500
0.39
1.00
0.50 1.50 Indifference
Graveoline
Vancomycin
500
3.13
500
3.13
1.00
1.00 2.00 Indifference
Ciprofloxacin
Erythromycin
1.562
0.781
0.781
0.39
0.50
0.50 1.00 Additive
Ciprofloxacin
Vancomycin
1.562
3.125
0.781
1.562
0.50
0.50 1.00 Additive
E. coli 
ATCC 25922
Graveoline
Erythromycin
1000
50
250
25
0.25
0.50 0.75 Partial synergy
Graveoline
Vancomycin
1000
250
250
125
0.25
0.50 0.75 Partial synergy
Ciprofloxacin
Erythromycin
0.039
50
0.019
1.562
0.50
0.03 0.53 Partial synergy
Ciprofloxacin
Vancomycin
0.039
250
0.002
7.813
0.05
0.13 0.18 Synergy
FICI < 0.5, synergy; 0.5 - 0.75, partial synergy; > 0.75 to 1.0, additive effect; > 1.0 to 4.0 indifference and > 4, antagonism (Orhan et al. 2005)
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agent than ciprofloxacin against S. aureus whereas it was 
inferior agent than ciprofloxacin against E. coli. 
The identification details of the isolated antimicrobial 
alkaloids are shown as follows:
Compound 1 2,3-dimethoxy-1-hydroxy-10-methylacridone 
[Arborinine]; C16H15NO4; MW: 285 g/mol; bright yellow 
fine needle-shaped crystals; MP: 175-176ºC, Rf: 0.67 
(CHCl3); IR (CHCl3) cm-1: 1641, 1591, 1556, 1463, 1322, 
1251, 1188, 1139, 1106, 1058, 989, 918, 849, 784, 753; 
UV/Vis λ
max
 (MeOH) nm (log ε): 230 (3.79), 274 (4.24), 
399 (3.41); 1H NMR (500 MHz, CDCl3): 14.73 (1H, s, 
1-OH), 8.39 (1 H, dd, J = 1.7 and 8.2 Hz, H-8), 7.70 (1H, 
m, H-6), 7.47 (1H, d, J = 8.6 Hz, H-5), 7.26 (1H, t, J = 
7.4 Hz, H-7), 6.24 (1H, s, H-4), 4.00 (3H, s, 2-OMe), 3.92 
(3H, s, 3-OMe), 3.82 (3H, s, N-Me); 13C NMR (100 MHz, 
CDCl3) δ: 180.6 (C-9), 159.2 (C-3) 155.9 (C-1), 141.8 
(C-10a), 140.3 (C-4a), 133.9 (C-6), 130.0 (C-2), 126.4 (C-
8), 121.4 (C-7), 120.50 (C-8a), 114.6 (C-5), 105.6 (C-9a), 
86.7 (C-4), 60.8 (2-OCH3), 55.9 (3-OCH3), 34.0 (N-CH3); 
MS (EI, 70 eV): m/z (%) = 285 [M + H+] (52), 270 (100), 
256 (15), 242 (85), 227 (5), 212 (12), 199 (59), 171 (12), 
143 (9), 115 (10).
Compound 2 4,7,8-trimethoxyfuro[2,3-b]quinoline 
[Skimmianine]; Formula: C14H13NO4   MW: 259 g/mol, 
colorless rhombohedral prisms; MP: 175-176ºC; Rf: 0.52 
(CHCl3); IR (CHCl3) cm-1: 1616, 1575, 1389, 1364, 1266, 
1088, 950; UV/Vis λ
max
 (MeOH) nm (log ε): 250 (4.30), 
332 (3.39); 1H NMR (500 MHz, CDCl3): 8.03 (1 H, d, J = 
9.5 Hz, H-5), 7.61 (1H, d, J = 2.5 Hz, H-2), 7.25 (1 H, d, J 
= 9.5 Hz, H-6), 7.06 (1 H, d, J = 2.5 Hz, H-3), 4.45 (3 H, s, 
4-OMe), 4.14 (3 H, s, 8-OMe), 4.05 (3 H, s, 7-OMe); 13C 
NMR (100 MHz, CDCl3) δ: 164.6 (C-9a), 157.5 (C-4), 152.4 
(C-8a), 143.1 (C-2), 142.1 (C-7), 141.2 (C-8), 118.3 (C-5), 
115.1 (C-3a), 112.1 (C-6), 104.7 (C-3), 102.1 (C-4a), 61.7 
(8-OCH3), 59.1 (4-OCH3), 56.8 (7-OCH3); MS (EI, 70 eV): 
m/z (%) = 259 [M + H+] (64), 230 (5), 216 (4), 172 (2).
Compound 3 1-methyl-2-[3’,4’-methylenedioxyphenyl]-4-
quinolone [Graveoline]; Formula: C18H17O3N; MW: 279 g/
mol; white amorphous powder; MP: 185-186ºC; Rf: 0.58 
(CHCl3: MeOH, 9:1); IR (CHCl3) cm-1: 1621, 1597, 1563, 
1486, 1446, 1250, 1036, 827, 760; UV/Vis λ
max
 (MeOH) nm 
(log ε): 243 (4.18), 324 (3.89), 336 (3.90); 1H NMR (500 
MHz, CDCl3): 8.50 (1 H, dd, J = 1.5 and 8.0 Hz, H-5), 
7.74 (1 H, t, J = 8.5 Hz, H-7), 7.57 (1 H, d, J = 8.5 Hz, 
H-8), 7.40 (1H, t, J = 8.0 Hz, H-6), 6.88 (1H, d, J = 1.5 Hz, 
H-2’), 6.91 (1H, s, H-3’), 6.88 (1H, d, J = 1.5, H-6’), 6.37 
(1H, s, H-3), 6.09 (2H, s, OCH2O), 3.70 (3H, s, N-Me); 
13C NMR (100 MHz, CDCl3) δ: 177.3 (C-4), 154.7 (C-2), 
148.8 (C-4’), 147.9 (C-5’), 141.9 (C-8a), 132.5 (C-2’), 
129.3 (C-1’), 126.7 (C-4a), 126.6 (C-7), 123.9 (C-6), 122.8 
(C-5), 116.1 (C-8), 112.5 (C-3), 109.0 (C-3’), 108.7 (C-6’), 
101.8 (OCH2O), 37.5 (N-CH3); MS (EI, 70 eV): m/z (%) = 
279 [M + H+] (60), 251 (100), 192 (17).
CONCLUSION
The synergistic action of the combination between 
graveoline, a natural quinolone alkaloid and erythromycin, 
a macrolide or vancomycin, a glycopeptide possesses a 
potential clinical significance as an alternative antimicrobial 
combination agent to be further researched for future 
benefit in overcoming or at least delaying the emergence 
of resistance in bacteria particularly against S. aureus.
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